| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2024-08-09 |
| タイトル |
|
|
タイトル |
Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody : JACCRO CC-16 |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
大北, 仁裕
奥山, 浩之
辻, 晃仁
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Chemotherapy in combination with anti-epidermal growth factor receptor (EGFR) antibody is considered a first-line treatment regimen for RAS wild-type and left-sided metastatic colorectal cancer (mCRC), whereas second-line treatment regimens have not yet been established. Few studies have prospectively evaluated second-line treatment with anti-vascular endothelial growth factor antibody after first-line anti-EGFR antibody therapy for RAS wild-type mCRC. |
|
言語 |
en |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Patients and methods: This non-randomized phase II trial investigated the clinical outcomes of second-line ramucirumab (RAM) plus fluorouracil, levofolinate, and irinotecan (FOLFIRI) after first-line anti-EGFR antibody in combination with doublet or triplet regimen in patients with RAS wild-type mCRC. The primary endpoint was the 6-month progression-free survival (PFS) rate. The secondary endpoints were PFS, overall survival (OS), objective response rate (ORR), rate of early tumor shrinkage (ETS), and safety. We hypothesized a threshold 6-month PFS rate of 30% and an expected 6-month PFS rate of 45%. Treatment was considered effective if the lower limit of the 90% confidence interval (CI) of the 6-month PFS rate was >0.30. |
|
言語 |
en |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Results: Ninety-two patients were enrolled in the study. The primary tumor was located on the left side in 86 (95.6%) patients. Twenty (22.0%) patients had received triplet plus cetuximab as previous therapy. Six-month PFS rate was 58.2% (90% CI 49.3% to 66.2%) with a median PFS of 7.0 months (95% CI 5.7-7.6 months). Median OS was 23.6 months (95% CI 16.5-26.3 months). The ORR and ETS rate were 10.7% and 16.9%, respectively, in 83 patients with measurable lesions. The 6-month PFS rate was comparable between patients previously treated with doublet and triplet regimens; however, median PFS was longer for the doublet regimen (7.4 versus 6.4 months, P = 0.036). |
|
言語 |
en |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Conclusions: Our study demonstrated prospectively that RAM plus FOLFIRI is an effective second-line treatment after anti-EGFR antibody-containing first-line therapy in RAS wild-type and left-sided mCRC. Furthermore, the results were similar for patients who were previously treated with triplet regimen. |
|
言語 |
en |
| bibliographic_information |
en : ESMO open
巻 8,
号 5,
発行日 2023-10
|
| 出版者 |
|
|
出版者 |
European Society for Medical Oncology |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Elsevier |
|
言語 |
en |
| item_10001_source_id_9 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2059-7029 |
| 権利 |
|
|
言語 |
en |
|
権利情報 |
© 2023 The Author(s). |
| 権利 |
|
|
言語 |
en |
|
権利情報Resource |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
|
権利情報 |
This is an open access article under the CC BY-NC-ND licence. |
| item_10001_relation_13 |
|
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
37703596 |
| 関連サイト |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1016/j.esmoop.2023.101636 |
| 関連サイト |
|
|
関連タイプ |
hasVersion |
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10594013/ |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| キーワード |
|
|
言語 |
ja |
|
主題Scheme |
Other |
|
主題 |
ramucirumab |
| キーワード |
|
|
言語 |
ja |
|
主題Scheme |
Other |
|
主題 |
colorectal cancer |
| キーワード |
|
|
言語 |
ja |
|
主題Scheme |
Other |
|
主題 |
RAS wild-type |
| キーワード |
|
|
言語 |
ja |
|
主題Scheme |
Other |
|
主題 |
chemotherapy |
https://doi.org/10.1016/j.esmoop.2023.101636
.png)
